Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

Wednesday, GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year ... by lower demand for Arexvy related to a more limited ACIP ...

Specialty medicines, which grew 19% in 2024, remain a key focus, with oncology sales nearly doubling to over £1.4 billion ... reflecting pressures on Arexvy and Shingrix in the U.S. However ...

Vaccine sales fell 14% to £2.21B, with Arexvy sales down 70% ... each impacting full year growth by 1 percentage point. Shingrix sales reached 848 million pounds, down 7% (-4% at constant ...

GSK reported a similar state of affairs Wednesday. Sales of its RSV vaccine Arexvy declined 69% year over year due to lower demand “related to a more limited recommendation ... for individuals ...

So if you do that, the end of 2024, we had about a 58% market share. So about 4.1 doses out of 7 million were with Arexvy. I think we're happy with that. The key thing is to preserve value and ...

After a blockbuster burst onto the market last year, sales of the RSV vaccine Arexvy nosedived this season ... rates to 848 million pound sterling ($1.06 billion) in the last three months of ...

driven by a 19% decline in sales of its flu shots and a 52% plunge for its respiratory treatment Arexvy. Shares are up 6.7% at 14.73 pounds.([email protected]) ...

Meanwhile, vaccine sales slipped by 4% for the year, driven by a sharp drop for its Arexvy lung disease treatment. Operating profits dropped by 40% to £4 billion due to a £1.8 billion settlement ...

driven by a sharp drop for its Arexvy lung disease treatment. Explore the key data from our strong 2024 performance. Operating profits dropped by 40% to £4 billion due to a £1.8 billion ...